ReviewTranslational lung cancer research2015
Treatment of advanced squamous cell carcinoma of the lung: a review.
Review in Translational lung cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed.
- Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial.Thoracic cancer · 2021Trial
- The inhibitory effect and targets of CRM197 on tumor growth in arsenic-transformed cells and lung cancer cells.Scientific reports · 2025Article
- Impact of piR_004530 reactivation in lung cancer: implications for recurrence and survival of lung squamous cell carcinoma patients.BMC medicine · 2025Article
- Real-Time Evolutionary Landscape of the Bronchial Epithelium and Corresponding Dynamic Immune Cell Alterations in Lung Squamous Cell Carcinogenesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Diagnostic and Prognostic Value of hsa_piR_022710, hsa_piR_019822, and hsa_piR_020840 in Early-Stage Non-Small-Cell Lung Cancer: Implications for Recurrence and Survival in Squamous Cell Carcinoma Patients.International journal of molecular sciences · 2025Article
- Genomic and Transcriptomic Profiles in Smokers and Never-Smokers Lung Squamous Cell Carcinoma Patients.Lung Cancer (Auckland, N.Z.) · 2025Article
- Identification of a prognostic gene signature in patients with cisplatin resistant squamous cell lung cancer.Journal of thoracic disease · 2024Article
- Article
- Article
- Prognostic analysis of lung squamous cell carcinoma patients with second primary malignancies: a SEER database study.Frontiers in oncology · 2024Article
- Licochalcone A induces cell cycle arrest and apoptosis via suppressing MAPK signaling pathway and the expression of FBXO5 in lung squamous cell cancer.Oncology reports · 2023Article
- Immune-active tumor-adjacent tissues are associated with favorable prognosis in stage I lung squamous cell carcinoma.iScience · 2023Article
- Whole-tumor histogram analysis of multi-parametric MRI for differentiating brain metastases histological subtypes in lung cancers: relationship with the Ki-67 proliferation index.Neurosurgical review · 2023Article
- The NRF2 antagonist ML385 inhibits PI3K-mTOR signaling and growth of lung squamous cell carcinoma cells.Cancer medicine · 2023Article
- [Licochalcone A induces cell cycle arrest in human lung squamous carcinoma cellsNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023Article
- Construction and validation of a prognostic model based on ten signature cell cycle-related genes for early-stage lung squamous cell carcinoma.Cancer biomarkers : section A of Disease markers · 2023Article
- The importance of enhancer methylation for epigenetic regulation of tumorigenesis in squamous lung cancer.Experimental & molecular medicine · 2022Article
- Molecular cytogenetic characterization of the urethane-induced murine lung cell line LA-4 as a model for human squamous cell lung cancer.Molecular and clinical oncology · 2022Article
- Clinical characteristics and gene mutation profiles of chronic obstructive pulmonary disease in non-small cell lung cancer.Frontiers in oncology · 2022Article
- Clinicopathological implications of lncRNAs, immunotherapy and DNA methylation in lung squamous cell carcinoma: a narrative review.Translational cancer research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains the single deadliest cancer both in the US and worldwide. The great majority of squamous cell carcinoma (SCC) is attributed to cigarette smoking, which fortunately is declining alongside cancer incidence. While we have been at a therapeutic plateau for advanced squamous cell lung cancer patients for several decades, recent observations suggest that we are on the verge of seeing incremental survival improvements for this relatively large group of patients. Current studies have confirmed an expanding role for immunotherapy [including programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibition], a potential opportunity for VEGFR inhibition, and even future targets in fibroblast growth factor receptor (FGFR) and PI3K-AKT that collectively should improve survival as well as quality of life for those affected by squamous cell lung cancer over the next decade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.